Linkedin
Facebook
Twitter
Youtube

23 Feb Luminary Therapeutics

Posted at 19:25h in by

Jeff Liter, President and CEO 

Oct. 12 | 11:00am | Oxford Biomedica Ballroom 

Minneapolis, MN 

(Private) 

In-person Presentation 

Luminary Therapeutics is a clinical-stage cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Our novel ligand-based CAR is designed to bind three targets and is set to enter the clinic in Q3 2022. Additionally, we have an allogeneic platform based on gamma delta cells. Luminary was founded by the team from B-MoGen that achieved a successful 5x exit in only three years. We are seeking Series A financing with venture firms or strategic partners to support our first clinical trial and development of our disruptive U-Receptor that can modulate antigen specificity. 

www.luminarytx.com 



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 10-12, 2023
Park Hyatt Aviara
Carlsbad, CA

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions